<p>Sight Sciences（纳斯达克代码：SGHT - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益为（$0.24），低于市场共识预期的（$0.19），差距为（$0.05），FiscalAI 报道。Sight Sciences 的净利润率为负 49.67%，股本回报率为负 55.72%。该公司本季度的收入为 1970 万美元，而市场共识预期为 1847 万美元。</p>
<p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
<h2>Sight Sciences 股价下跌 0.7%</h2>
<p>周三交易时段，纳斯达克 SGHT 股价下跌 $0.03，报 $4.30。该公司股票交易量为 183,982 股，而其平均交易量为 316,939 股。该股票的 50 日简单移动平均为$4.09，200 日简单移动平均为$5.83。Sight Sciences 的 1 年最低价为$2.81，最高价为$9.24。该公司的市值为$2.3392 亿，市盈率为-5.73，贝塔值为 2.38。公司当前比率为 10.22，速动比率为 9.52，债务与股本比率为 0.63。</p>
<h2>内部人士下注</h2>
<p>在相关消息中，首席技术官 David Badawi 于 4 月 2 日星期四出售了 8,168 股公司的股票，交易价格为每股平均$3.48，总交易额为$28,424.64。出售完成后，首席技术官持有公司股票 1,990,290 股，价值$6,926,209.20。此交易代表其持股比例下降了 0.41%。该交易已在向 SEC 提交的文件中披露，文件可在 SEC 网站上查阅。此外，内部人士 Jeremy B. Hayden 于 4 月 6 日星期一出售了 13,761 股公司的股票，交易价格为每股平均$3.55，总价值为$48,851.55。出售后，该内部人士直接持有公司股票 369,770 股，价值$1,312,683.50。这代表其持股比例下降了 3.59%。该交易的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士共出售了 61,273 股公司股票，价值$221,764。公司内部人士持有公司股票的 28.90%。</p>
<h2>机构投资者对 Sight Sciences 的看法</h2>
<p>几家大型投资者最近增加或减少了对 SGHT 的持股。Integral Health Asset Management LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$3,370,000。Invesco Ltd.在第四季度收购了 Sight Sciences 的新股份，价值约$2,791,000。Walleye Capital LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$2,332,000。Informed Momentum Co LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$1,299,000。最后，Millennium Management LLC 在第四季度将其在 Sight Sciences 的持股增加了 99.4%。Millennium Management LLC 现在持有 266,919 股公司股票，价值$2,117,000，此前在该期间内又收购了 133,073 股。机构投资者和对冲基金持有公司 55.51% 的股份。</p>
<h2>华尔街分析师的看法</h2>
<p>一些股票分析师最近对 SGHT 股票发布了报告。花旗集团将 Sight Sciences 的目标价从$9.10 下调至$6.50，并在 3 月 6 日的研究报告中对该公司给予了 “中性” 评级。Cantor Fitzgerald 在 3 月 2 日的研究报告中对 Sight Sciences 设定了$8.00 的目标价。瑞银集团将 Sight Sciences 的目标价从$12.00 下调至$11.00，并在 3 月 6 日的研究报告中对该公司给予了 “买入” 评级。Stifel Nicolaus 在 3 月 2 日的研究报告中将 Sight Sciences 的目标价从$6.00 上调至$8.00，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 4 月 10 日的研究报告中重申了对 Sight Sciences 股票的 “卖出（d-）” 评级。五位分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价为$8.31。</p>
<p><strong>查看我们对 Sight Sciences 的最新分析</strong></p>
<h2>关于 Sight Sciences</h2>
<p>（获取免费报告）</p>
<p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的产品。公司的旗舰产品包括 OMNI®外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare®系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
<p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票，胜过 Sight Sciences</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Sight Sciences 吗？</h2>
<p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Sight Sciences 并不在名单上。</p>
<p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

SGHT

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Sight Sciences (NASDAQ:SGHT) 发布了季度财报，每股收益为（$0.24），低于预期的（$0.19）。收入为 1970 万美元，超过了 1847 万美元的预期。该公司的股本回报率为负的 55.72%，净利润率为负的 49.67%。股票下跌 0.7%，报 4.30 美元。最近的内部交易包括首席技术官 David Badawi 出售 8168 股，内部人士 Jeremy B. Hayden 出售 13761 股。机构投资者持有该公司 55.51% 的股份，分析师的评级意见不一，普遍持有评级，平均目标价为 8.31 美元</p>

<p>Sight Sciences (NASDAQ:SGHT - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.05), FiscalAI reports. Sight Sciences had a negative net margin of 49.67% and a negative return on equity of 55.72%. The firm had revenue of $19.70 million during the quarter, compared to the consensus estimate of $18.47 million.</p>
<div class="lb-trans"><p>Sight Sciences（纳斯达克代码：SGHT - 获取免费报告）于周三发布了其财报。公司报告本季度每股收益为（$0.24），低于市场共识预期的（$0.19），差距为（$0.05），FiscalAI 报道。Sight Sciences 的净利润率为负 49.67%，股本回报率为负 55.72%。该公司本季度的收入为 1970 万美元，而市场共识预期为 1847 万美元。</p>
</div><p>Get <strong>Sight Sciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Sight Sciences</strong> 的提醒：</p>
</div><h2>Sight Sciences Trading Down 0.7%</h2>
<div class="lb-trans"><h2>Sight Sciences 股价下跌 0.7%</h2>
</div><p>NASDAQ SGHT traded down $0.03 during trading hours on Wednesday, hitting $4.30. 183,982 shares of the company's stock were exchanged, compared to its average volume of 316,939. The stock has a 50-day simple moving average of $4.09 and a 200 day simple moving average of $5.83. Sight Sciences has a 1-year low of $2.81 and a 1-year high of $9.24. The firm has a market cap of $233.92 million, a price-to-earnings ratio of -5.73 and a beta of 2.38. The company has a current ratio of 10.22, a quick ratio of 9.52 and a debt-to-equity ratio of 0.63.</p>
<div class="lb-trans"><p>周三交易时段，纳斯达克 SGHT 股价下跌 $0.03，报 $4.30。该公司股票交易量为 183,982 股，而其平均交易量为 316,939 股。该股票的 50 日简单移动平均为$4.09，200 日简单移动平均为$5.83。Sight Sciences 的 1 年最低价为$2.81，最高价为$9.24。该公司的市值为$2.3392 亿，市盈率为-5.73，贝塔值为 2.38。公司当前比率为 10.22，速动比率为 9.52，债务与股本比率为 0.63。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In related news, CTO David Badawi sold 8,168 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total transaction of $28,424.64. Following the completion of the sale, the chief technology officer owned 1,990,290 shares of the company's stock, valued at $6,926,209.20. This trade represents a 0.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Jeremy B. Hayden sold 13,761 shares of the firm's stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $48,851.55. Following the sale, the insider directly owned 369,770 shares of the company's stock, valued at $1,312,683.50. This represents a 3.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 61,273 shares of company stock worth $221,764. Company insiders own 28.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，首席技术官 David Badawi 于 4 月 2 日星期四出售了 8,168 股公司的股票，交易价格为每股平均$3.48，总交易额为$28,424.64。出售完成后，首席技术官持有公司股票 1,990,290 股，价值$6,926,209.20。此交易代表其持股比例下降了 0.41%。该交易已在向 SEC 提交的文件中披露，文件可在 SEC 网站上查阅。此外，内部人士 Jeremy B. Hayden 于 4 月 6 日星期一出售了 13,761 股公司的股票，交易价格为每股平均$3.55，总价值为$48,851.55。出售后，该内部人士直接持有公司股票 369,770 股，价值$1,312,683.50。这代表其持股比例下降了 3.59%。该交易的披露信息可在 SEC 文件中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去的九十天里，内部人士共出售了 61,273 股公司股票，价值$221,764。公司内部人士持有公司股票的 28.90%。</p>
</div><h2>Institutional Investors Weigh In On Sight Sciences</h2>
<div class="lb-trans"><h2>机构投资者对 Sight Sciences 的看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in SGHT. Integral Health Asset Management LLC acquired a new stake in Sight Sciences during the fourth quarter worth approximately $3,370,000. Invesco Ltd. acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $2,791,000. Walleye Capital LLC acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $2,332,000. Informed Momentum Co LLC acquired a new stake in Sight Sciences in the fourth quarter valued at approximately $1,299,000. Finally, Millennium Management LLC grew its stake in Sight Sciences by 99.4% in the fourth quarter. Millennium Management LLC now owns 266,919 shares of the company's stock valued at $2,117,000 after acquiring an additional 133,073 shares during the period. Institutional investors and hedge funds own 55.51% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 SGHT 的持股。Integral Health Asset Management LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$3,370,000。Invesco Ltd.在第四季度收购了 Sight Sciences 的新股份，价值约$2,791,000。Walleye Capital LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$2,332,000。Informed Momentum Co LLC 在第四季度收购了 Sight Sciences 的新股份，价值约$1,299,000。最后，Millennium Management LLC 在第四季度将其在 Sight Sciences 的持股增加了 99.4%。Millennium Management LLC 现在持有 266,919 股公司股票，价值$2,117,000，此前在该期间内又收购了 133,073 股。机构投资者和对冲基金持有公司 55.51% 的股份。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师的看法</h2>
</div><p>A number of equities analysts have recently issued reports on SGHT shares. Citigroup lowered their price objective on Sight Sciences from $9.10 to $6.50 and set a &#34;neutral&#34; rating for the company in a research report on Friday, March 6th. Cantor Fitzgerald set a $8.00 price objective on Sight Sciences in a research report on Monday, March 2nd. UBS Group lowered their price objective on Sight Sciences from $12.00 to $11.00 and set a &#34;buy&#34; rating for the company in a research report on Friday, March 6th. Stifel Nicolaus raised their price objective on Sight Sciences from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, March 2nd. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Sight Sciences in a research report on Friday, April 10th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of &#34;Hold&#34; and an average price target of $8.31.</p>
<div class="lb-trans"><p>一些股票分析师最近对 SGHT 股票发布了报告。花旗集团将 Sight Sciences 的目标价从$9.10 下调至$6.50，并在 3 月 6 日的研究报告中对该公司给予了 “中性” 评级。Cantor Fitzgerald 在 3 月 2 日的研究报告中对 Sight Sciences 设定了$8.00 的目标价。瑞银集团将 Sight Sciences 的目标价从$12.00 下调至$11.00，并在 3 月 6 日的研究报告中对该公司给予了 “买入” 评级。Stifel Nicolaus 在 3 月 2 日的研究报告中将 Sight Sciences 的目标价从$6.00 上调至$8.00，并给予该股票 “买入” 评级。最后，Weiss Ratings 在 4 月 10 日的研究报告中重申了对 Sight Sciences 股票的 “卖出（d-）” 评级。五位分析师对该股票给予了买入评级，三位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的共识评级为 “持有”，平均目标价为$8.31。</p>
</div><p><strong>View Our Latest Analysis on Sight Sciences</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Sight Sciences 的最新分析</strong></p>
</div><h2>About Sight Sciences</h2>
<div class="lb-trans"><h2>关于 Sight Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.</p>
<div class="lb-trans"><p>Sight Sciences, Inc 是一家医疗设备公司，专注于开发和商业化微创治疗慢性眼病的产品。公司的旗舰产品包括 OMNI®外科系统，旨在解决眼睛自然排水通道中的多个阻力点，以降低青光眼患者的眼内压，以及 TearCare®系统，这是一种可穿戴设备，通过针对性的热脉冲治疗来治疗睑板腺功能障碍和干眼病。</p>
</div><p>Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.</p>
<div class="lb-trans"><p>自 2012 年成立并在纳斯达克上市以来，Sight Sciences 一直追求将研究驱动的产品开发与直接销售模式相结合的战略。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Sight Sciences</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Sight Sciences</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0dIVA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=SGHT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Sight Sciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Sight Sciences 吗？</h2>
</div><p>Before you consider Sight Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Sight Sciences 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Sight Sciences 并不在名单上。</p>
</div><p>While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Sight Sciences 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Sight Sciences（NASDAQ:SGHT）公布季度财报结果